Onchee Yu, MS, is a biostatistician who has extensive experience in statistical applications to electronic health records (EHR) data, which she has contributed to studies related to women’s health, pharmacoepidemiology, and vaccine safety and effectiveness. Ms. Yu has been a key member of the immunization research program at Kaiser Permanente Washington Health Research Institute (KPWHRI) over 20 years. Her work focuses on applying statistical methods to evaluate vaccine effectiveness, side effects, and safety. In collaboration with KPWHRI biostatisticians Jennifer Nelson, PhD, and Andrea Cook, PhD, Ms. Yu developed and improved statistical methods for monitoring the safety of postmarketing vaccines in the Vaccine Safety Datalink project.
Much of Ms. Yu's recent research is in pharmacoepidemiology, which is studying how drugs are used in a population and their impact on public health. She is an expert in statistical analysis in a complex, clinically important area — determining if medicine for one condition (for example, cardiovascular medications) affects risk of other illnesses (for example, dementia).
Addiction is another scientific area that Ms. Yu is involved in. In particular, she is a biostatistician on the PROUD (PRimary care Opioid Use Disorders) trial, a pragmatic implementation trial conducted in 6 diverse health systems to evaluate a program for increasing medication treatment for opioid use disorders within primary care settings.
Ms. Yu is also heavily involved in aging and geriatric research including collaborations with scientists on the Adult Changes in Thought (ACT) Study, a long-standing and ongoing longitudinal cohort study exploring risk factors related to dementia, Alzheimer's disease, and healthy aging.
Ms. Yu obtained her master’s degree in biostatistics from the University of Washington in 1999. She also has prior experience and contribution to research in cancer and women’s health.
Survival analysis; classification and regression tree analysis
Biostatistics; medication use and cancer outcomes
Biostatistics; vaccine safety and efficacy; postmarketing vaccine safety study design and analysis
Biostatistics; incidence and prevalence estimations; validation of diagnosis codes; automated case-finding algorithms
Biostatistics; medication use and cancer outcomes; postmarketing drug and vaccine safety study design and analysis; safety signal detection methods
Gray SL, Dublin S, Yu O, Walker RL, Anderson ML, Hubbard R, Crane PK, Larson EB. Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ. 2016 Feb 2;352:i90. doi: 10.1136/bmj.i90. PubMed
Nelson JC, Wellman R, Yu O, Cook AJ, Maro JC, Ouellet-Hellstrom R, Boudreau D, Floyd JS, Heckbert SR, Pinheiro S, Reichman M, Shoaibi A. A synthesis of current surveillance planning methods for the sequential monitoring of drug and vaccine adverse effects using electronic health care data. EGEMS (Wash DC). 2016 Sep 6;4(1):1219. eCollection 2016. PubMed
Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM. Breast cancer recurrence in relation in antidepressant use. Cancer Causes Control. 2015 Oct 30. [Epub ahead of print]. PubMed
Dublin S, Walker RL, Gray SL, Hubbard RA, Anderson ML, Yu O, Crane PK, Larson EB. Prescription opioids and risk of dementia or cognitive decline: a prospective cohort study. J Am Geriatr Soc. 2015 Aug;63(8):1519-26. doi: 10.1111/jgs.13562. PubMed
Calip GS, Yu O, Hoskins KF, Boudreau DM. Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control. 2015 May 9. [Epub ahead of print]. PubMed
A trial led by KPWHRI researchers found that adding nurse care managers helped more people get needed treatment.
Researchers gain better understanding of polycystic ovary syndrome's impact in U.S.
Researchers find a relationship between prescribed central nervous system-active medications and increased risk of falling among older people with dementia.